全关节置换术后使用利伐沙班而未围手术期使用氨甲环酸与出血并发症风险增加相关
该研究利用医疗保健数据库纳入2015至2021年间初次全膝和全髋关节置换患者,比较住院期间使用利伐沙班且手术当日使用氨甲环酸者与未使用氨甲环酸者。多变量分析显示,使用氨甲环酸者 aggregate 出血并发症、输血、急性贫血、深静脉血栓和肺栓塞风险降低,卒中和心肌梗死风险无差异。作者认为关节置换外科医生应考虑对使用利伐沙班的初次全髋和全膝置换患者给予氨甲环酸。
要点
- 使用利伐沙班加氨甲环酸者 aggregate 出血并发症 aOR 0.7(95%CI 0.7-0.7,P<0.001),输血 aOR 0.4(95%CI 0.4-0.4,P<0.001)。
- 使用利伐沙班加氨甲环酸者急性贫血 aOR 0.7(95%CI 0.7-0.8,P<0.001),深静脉血栓 aOR 0.8(95%CI 0.7-0.9,P<0.001),肺栓塞 aOR 0.8(95%CI 0.7-0.9,P=0.012)。
- 卒中和心肌梗死风险两组无差异(aOR 0.9,95%CI 0.7-1.1,P=0.31;aOR 0.9,95%CI 0.7-1.1,P=0.305)。
核心结论
- 围手术期给予氨甲环酸降低了接受利伐沙班患者的出血并发症风险,且未增加血栓栓塞风险。
- 作者认为关节置换外科医生应考虑对使用利伐沙班的初次全髋和全膝置换患者给予氨甲环酸。
研究设计与样本
- 利用医疗保健数据库识别2015至2021年间所有初次全膝置换和全髋置换患者。
- 共纳入161,585例全关节置换患者(全膝置换67.3%,全髋置换32.7%),其中41,899例(25.9%)仅使用利伐沙班,119,686例(74.1%)使用利伐沙班加氨甲环酸。
- 比较住院期间使用利伐沙班且手术当日使用氨甲环酸者与未使用氨甲环酸者,采用单变量和多变量回归分析评估90天出血、血栓栓塞和医疗术后结局差异。
主要发现
- 使用利伐沙班加氨甲环酸者较仅使用利伐沙班者 aggregate 出血并发症风险降低(aOR 0.7,95%CI 0.7-0.7,P<0.001)。
- 使用利伐沙班加氨甲环酸者较仅使用利伐沙班者输血风险降低(aOR 0.4,95%CI 0.4-0.4,P<0.001)。
- 使用利伐沙班加氨甲环酸者较仅使用利伐沙班者急性贫血风险降低(aOR 0.7,95%CI 0.7-0.8,P<0.001)。
- 使用利伐沙班加氨甲环酸者较仅使用利伐沙班者深静脉血栓风险降低(aOR 0.8,95%CI 0.7-0.9,P<0.001),肺栓塞风险降低(aOR 0.8,95%CI 0.7-0.9,P=0.012)。
- 两组卒中和心肌梗死风险无差异(aOR 0.9,95%CI 0.7-1.1,P=0.31;aOR 0.9,95%CI 0.7-1.1,P=0.305);按手术类型亚组分析显示全髋置换和全膝置换后 aggregate 出血并发症、输血和急性贫血风险均降低。
临床怎么用
- 作者认为关节置换外科医生应考虑对使用利伐沙班的初次全髋和全膝置换患者给予氨甲环酸。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rivaroxaban provides effective venous thromboembolic prophylaxis, but there are concerns about associated bleeding in total joint arthroplasty (TJA) patients. This study aimed to investigate whether the perioperative administration of tranexamic acid (TXA) in TJA patients receiving rivaroxaban for thromboprophylaxis is associated with a reduced risk of postoperative bleeding complications. METHODS: A healthcare database was utilized to identify all primary total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients between 2015 and 2021. Patients receiving rivaroxaban during their in-hospital admission who also received TXA on the day of surgery were compared to those who did not receive TXA. Univariate and multivariable regression analyses assessed differences in 90-day bleeding, thromboembolic, and medical postoperative outcomes between cohorts. In total, 161,585 TJA patients were identified (TKA: 67.3%; THA: 32.7%), of which 41,899 (25.9%) received rivaroxaban alone, and 119,686 (74.1%) received rivaroxaban plus TXA. RESULTS: Multivariable analyses found that patients who received rivaroxaban and TXA had a reduced risk of aggregate bleeding complications (adjusted odds ratio [aOR] 0.7, 95% confidence interval [CI]: 0.7 to 0.7, P < 0.001), transfusion (aOR 0.4, 95% CI: 0.4 to 0.4, P < 0.001), acute anemia (aOR 0.7, 95% CI: 0.7 to 0.8, P < 0.001), deep vein thrombosis (aOR 0.8, 95% CI: 0.7 to 0.9, P < 0.001), and pulmonary embolism (aOR 0.8, 95% CI: 0.7 to 0.9, P = 0.012). No differences between cohorts were observed for the risk of stroke (aOR 0.9, 95% CI: 0.7 to 1.1, P = 0.31) and myocardial infarction (aOR 0.9, 95% CI: 0.7 to 1.1, P = 0.305). Procedure-specific subanalysis demonstrated a reduced risk of aggregate bleeding complications, transfusion, and acute anemia following THA and TKA. CONCLUSIONS: Perioperative administration of TXA reduced the risk of bleeding complications without increasing thromboembolic risk among patients receiving rivaroxaban. Arthroplasty surgeons should consider administering TXA to primary THA and TKA patients receiving rivaroxaban.
引用
- Palmer RC, Telang SS, Dobitsch A, et al. Rivaroxaban Utilization Without Perioperative Tranexamic Acid Is Associated With an Increased Risk of Bleeding Complications Following Total Joint Arthroplasty. J Arthroplasty. 2025. PMID: 40339926. doi:10.1016/j.arth.2025.04.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。